Island Pharmaceuticals Ltd (ASX:ILA) has now dosed all eight subjects in the second cohort of its ISLA-101 Single Ascending Dose (SAD) study. ISLA-101 is a.
Market is going to be surprised, says Firebrick as it prepares launch antiviral nasal spray theaustralian.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaustralian.com.au Daily Mail and Mail on Sunday newspapers.
Island Pharmaceuticals Ltd (ASX:ILA), a leader in antiviral drug development, has initiated the first cohort dosing in its single ascending dose (SAD) study.
It’s been a difficult quarter for the biotech sector, with economies struggling to recover from high inflation making for a small appetite for risk. The ASX.